跳至主導覽
跳至搜尋
跳過主要內容
國立成功大學 首頁
English
中文
在 國立成功大學 搜尋內容
首頁
概要
研究單位
研究成果
專案
學生論文
設備
獎項
活動
查看斯高帕斯 (Scopus) 概要
許 耿福
教授
婦產學科
https://orcid.org/0000-0002-2698-4971
電子郵件
d5580
mail.ncku.edu
tw
h-index
4038
引文
34
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
1995 …
2025
每年研究成果
概覽
指紋
網路
專案
(19)
研究成果
(129)
類似的個人檔案
(6)
監製作品
(4)
指紋
查看啟用 Keng-Fu Hsu 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Ovarian Cancer
100%
Aptamer
57%
Neoplasm
47%
Clear Cell Carcinoma
35%
Uterine Cancer
26%
Uterine Fibroid
26%
Krukenberg Tumor
25%
Immunohistochemistry
23%
Cancer Cell
22%
Malignant Neoplasm
22%
Biological Marker
20%
Tumor Cell
19%
Gynecological Oncology
19%
Phosphotransferase
19%
BRCA2
17%
Cell Proliferation
17%
Cervical Cancer
17%
BRCA1
17%
Uterine Cervix Carcinoma
17%
DNA Immunization
17%
Cancer Diagnosis
16%
Gynecological Cancer Surgery
15%
Doppler Ultrasound
15%
Doppler Flowmetry
15%
Vascularity
15%
Ascites
15%
Microvessel
14%
Radiation Therapy
14%
Cell-Free DNA
13%
Proliferating Cell Nuclear Antigen
13%
Protein Binding
12%
Cancer Biomarkers
12%
Lung Cancer
11%
Liquid Biopsy
10%
Breast Cancer
10%
Metastatic Carcinoma
10%
Cancer Growth
10%
Hazard Ratio
10%
Drug Resistance
10%
Germ Cell
10%
Cancer Tissue
10%
DNA Damage
9%
Hysterectomy
9%
Blood Flow
9%
Female Genital Tract Cancer
9%
Tumor Antigen
9%
Messenger RNA
9%
Overall Survival
8%
Lower Limb Lymphedema
8%
Lymphedema
8%
Keyphrases
Integrated Microfluidic Device
61%
Ovarian Cancer
58%
Aptamer
53%
Tissue Sampling
36%
Microfluidic System
33%
Clinical Tissues
22%
SELEX
21%
Serous Ovarian Cancer
17%
Heat Shock Protein 70 (HSP70)
17%
Autonomous Microfluidics
17%
Variant Impact
17%
Susceptibility Variants
17%
Germline Susceptibility
17%
High-throughput
17%
Ovarian Tissue
14%
Cancer Diagnosis
13%
Immunohistochemical Staining
13%
Magnetic Beads
13%
FXYD2
13%
Cancer Tissue
13%
Ovarian Cancer Cells
13%
Ovarian Cancer Biomarkers
11%
Tissue Slide
11%
Aptamer Selection
11%
Micro-incubator
11%
Squamous Cell Carcinoma Antigen
10%
Early-stage Cervical Cancer
10%
Tumor Cells
10%
Enrichment Method
9%
High Affinity
9%
Early-stage Ovarian Cancer
9%
Gynecological Cancer Surgery
8%
Lysosomal Compartment
8%
Therapeutic Strategies
8%
Clinical Outcomes
8%
Licorice
8%
CCL24
8%
Licochalcone A
8%
Prognostic Ability
8%
Surface-enhanced Raman Scattering Tag
8%
Stage III Colorectal Cancer
8%
Uterine Cervical Cancer
8%
Cervical Cancer Prevention
8%
Clinical Treatment
8%
Uterine Serous Carcinoma
8%
Combined Therapeutic
8%
Crown Structure
8%
BEZ235
8%
Moving Wall
8%
Cingulin
8%
Immunology and Microbiology
Cancer Cell
34%
Vaccine Efficacy
30%
Replicon
26%
Sindbis virus
26%
DNA Immunization
20%
Cytokine
20%
Blood Plasma
19%
Cancer Immunotherapy
19%
Mycobacterium Tuberculosis
17%
RNA Vaccine
17%
Hematopoietic Cell
17%
CD14
17%
Prognostic Biomarker
14%
Cell Migration
14%
Epithelial Mesenchymal Transition
13%
Survival Rate
13%
Protein Binding
12%
Wild Type
12%
Cancer Tissue
12%
Cell Invasion
11%
Cell Proliferation
11%
Quantitative Reverse Transcription Polymerase Chain Reaction
11%
Human Papillomavirus Type 16
11%
Tumor Antigen
11%
Germ Cell
10%
Tumor Volume
10%
CD16
10%
Squamous Cell Carcinoma Antigen
10%
Tumor Cell
9%
Human Alphaherpesvirus 1
9%
Tight Junction
8%
CCL24
8%
Lysosome Associated Membrane Protein 1
8%
Cell Surface
8%
Carcinoma Cell
8%
Tumor Immunity
8%
Colony Stimulating Factor 1 Receptor
8%
Drug Resistance
8%
CD68
8%
Multiplex Polymerase Chain Reaction
8%
Epidermal Growth Factor
8%
Epithelial Cell Adhesion Molecule
8%
Neutralization
8%
CD163
8%
Phage Display
8%
Somatomedin C
8%
Protein Processing
8%
Cell Motility
8%
Vascularization
8%
Flt3 Ligand
8%
